Key facts
- It has raised $77.3M; the latest was Accelerator/Incubator in Jul 2025.
- Notable investors include STIC Ventures, Partners Investment, KB Securities, UTC Investment, Yuanta Investment — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Cureverse
- ·The full record, as it builds
Funding rounds
No funding rounds for Cureverse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cureverse
Operator of a pharmaceutical research and development company intended for the treatment of brain diseases and multiple sclerosis. The company develops small-molecule drugs for Alzheimer's and Parkinson's disease, ulcerative colitis, and multiple sclerosis, as well as nephritis, and overcomes the cardiac side effects, helping doctors to improve human health and quality of life.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 7
- Website
- cureverse.co.kr/
- Ownership
- Privately Held (backing)
Cureverse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cureverse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cureverse in its N-PORT filings yet. We sweep new filings monthly.